Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications
Unlocking the potential of T cell engagers in solid tumors.
Journal: Cancer cell
Published: March 12, 2026
Assessing contribution of effect in oncology combination therapies: lessons learned to inform and optimize future registrational trial designs.
Journal: The oncologist
Published: January 13, 2026
Assessing Contribution of Effect in Oncology Combination Therapies: Lessons Learned to Inform and Optimize Future Registrational Trial Designs.
Journal: The oncologist
Published: January 13, 2026
Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data.
Journal: Cancer research communications
Published: December 05, 2024
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: November 03, 2024
Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 22, 2024
A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol.
Journal: Clinical lung cancer
Published: April 09, 2024
Acquired Cross-resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC paralogs.
Journal: bioRxiv : the preprint server for biology
Published: July 10, 2023
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: March 30, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Journal: Cancer discovery
Published: February 07, 2022
Last Updated: 09/26/2026